李广哲

男， 大连理工大学， 教授/研究员/教授级高工或同等级别

学习/工作经历

2002.09-2006.07 大连理工大学制药工程，工学学士
2006.09-2009.07 大连理工大学药物工程，理学硕士
2009.10-2013.03 日本东北大学药学研究科，药学博士
2013.04-2014.04 日本东北大学药学研究科，助教
2014.05-2015.09 东京工业大学化学生命科学研究所，助教
2015.12-2021.12 大连理工大学化工学院制药工程系，副教授
2022.01 至今　　 大连理工大学化工学院制药工程系，教授
2016.10 至今　　 大连理工大学化工学院制药工程系，教工党支部书记兼副系主任

研究领域和兴趣

药物化学、纳米医学

主要业绩

面向人民生命健康，聚焦恶性肿瘤等重大疾病的防治，围绕肿瘤靶向治疗的新方法、新靶点和新药物开展应用基础研究。近五年发表SCI学术论文23篇，以通讯/一作发表于Science Advances, Angew. Chem. Int. Ed.，Advanced Science 等期刊。授权国家发明专利12件。主持撰写Elsevier出版社英文专著Brain Targeted Drug Delivery System章节。担任S mart Molecules 青年编委。担任辽宁省细胞生物学学会淋巴细胞肿瘤及头颈部肿瘤医工融合专业委员会常务理事、辽宁省化工学会医药化工专业委员会委员、大连市药学会常务理事等。

代表成果

1) Wang Y, Li G*, Su J, Liu Y, Zhang X, Zhang G, Wu Z, Li J, Wang X, Zhang Y, Bai M, Yao Y, Wang R, Shao K*. Tumor-Associated Macrophages Nano-Reprogrammers Induce “Gear Effect” to Empower Glioblastoma Immunotherapy[J]. Small, 2025, 2406839. DOI:10.1002/smll.202406839
2) Wang, Y.; Li, G.*; Su, J.; Liu, Y.; Zhang, X.; Zhang, G.; Wu, Z.; Li, J.; Zhang, Y.; Wang, X.; Yang, Z.; Wang, R.; Wang, C.; Wang, L.; Sun, F.; Zhao, W.; Wang, X.; Peng, X.; Shao, K.*; Spatiotemporal Controllable Sono-Nanovaccines Driven by Free-Field Based Whole-Body Ultrasound for Personalized Cancer Therapy. Adv. Sci., 2024, 11, 2307920. DOI:10.1002/advs.202307920
3) Wang, L.; Li, G.*; Cao, L.; Shao, K.; Li, Y.; Zhang, X.; Zhao, J.; Zhao, W.* A novel water-soluble chlorin-based photosensitizer for low-fluence photodynamic therapy. ACS Pharmacol. Transl. Sci., 2022, 2, 110-117. DOI:10.1021/acsptsci.1c00249
4) Wang, L.; Li, G.*; Cao, L.; Dong, Y.; Wang, Y.; Wang, S.; Li, Y.; Guo, X.; Zhang, Y.; Sun, F.; Du, X.; Su, J.; Li, Q.; Peng X.; Shao, K.*; Zhao, W.* An Ultrasound-Driven Immune Boosting Molecular Machine for Systemic Tumor Suppression. Sci. Adv., 2021, 7, eabj4796. DOI: 10.1126/sciadv.abj4796
5) Li, G.*; Shao, Y.; Pan Y.; Li, Y.; Wang, Y.; Wang, L.; Wang, X.; Shao, K.; Wang, S.; Liu, N.; Zhang, J.; Zhao, W.; Nakamura, H. Total synthesis and biological evaluation of 7-Hydroxyneolamellarin A as hypoxia-inducible factor-1α inhibitor for cancer therapy. Bioorg. Med. Chem. Lett., 2021, 50, 128338. DOI: 10.1016/j.bmcl.2021.128338
6) Wang, S.; Wang, X.; Shao, Y.; Shao, K.; Wang, Y.; Guo, X.; Dong, H.; Zhao, W.; Li, Y.; Li, G.* Synthesis and evaluation of 3-(phenylethynyl)-1,1′-biphenyl-2-carboxylate derivatives as new HIF-1 inhibitors. Bioorg. Chem., 2021, 116, 105298. DOI: 10.1016/j.bioorg.2021.105298
7) Li, G.*; Wang, C.; Li, Y.; Shao, K.; Yu, G.; Wang, S.; Guo, X.; Zhao, W.; Nakamura, H. Zinc(ii)-catalyzed intramolecular hydroarylation-redox cross-dehydrogenative coupling of N-propargylanilines with diverse carbon pronucleophiles: facile access to functionalized tetrahydroquinolines. Chem. Commun., 2020, 7333-7336. DOI: 10.1039/d0cc02921a
8) Li, Y.; Li, G.*; Dong, Y.; Ma, X.; Dong, H.; Wu, Q.; Zhao, W.* Orobanone analogues from acid-promoted aromatization rearrangement of curcumol inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays. Bioorg. Chem., 2019, 85, 357-363. DOI: 10.1016/j.bioorg.2019.01.013
9) Li, G.; Ban, H.; Nakamura, H. Design of Carborane‐Based Hypoxia‐Inducible Factor Inhibitors. In: Evamarie H, Clara V T (Eds.), Boron‐Based Compounds: Potential and Emerging Applications in Medicine, Wiley, 2018, 35-59.
10) Li, G.; Nakamura, H.* Synthesis of 2-Indolyltetrahydroquinolines by Zinc(II)-Catalyzed Intramolecular Hydroarylation-Redox Cross-Dehydrogenative Coupling of N-Propargylanilines with Indoles. Angew. Chem. Int. Ed., 2016, 55, 6758-6761. DOI: 10.1002/anie.201602416

*以上信息由高级会员个人更新和维护。